Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Steven Chang was appointed as President at Simulations Plus, Inc..
- Action
- appointed
- Role
- President
Exact text from the filing
Steven Chang, the Chief Executive Officer of Immunetrics pre-Merger, was appointed as President of the Surviving Corporation
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Simulations Plus, Inc. entered into Agreement and Plan of Merger with Immunetrics, Inc. and LaunchCyte LLC, as representative of the stockholders of Immunetrics valued at $13,705,082.50 (effective 2023-06-16).
- Action
- entry
- Agreement
- merger
- Counterparty
- Immunetrics, Inc. and LaunchCyte LLC, as representative of the stockholders of Immunetrics
- Value
- $13,705,082.50
- Effective
- 2023-06-16
Exact text from the filing
On June 16, 2023, Simulations Plus, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, Insight Merger Sub, Inc., a wholly-owned subsidiary of the Company (“Merger Sub”), Immunetrics, Inc. (“Immunetrics”), a company specializing in quantitative systems pharmacology modeling, and LaunchCyte LLC, as representative of the stockholders of Immunetrics (the “Stockholder Representative”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.7
Simulations Plus, Inc. entered into Earnout Agreement with the Company, Merger Sub, Immunetrics and the Stockholder Representative valued at up to $8.0 million of Earnout Payments (effective 2023-06-16).
- Action
- entry
- Counterparty
- the Company, Merger Sub, Immunetrics and the Stockholder Representative
- Value
- up to $8.0 million of Earnout Payments
- Effective
- 2023-06-16
Exact text from the filing
Pursuant to the Earnout Agreement, the Company shall pay the Equityholders an aggregate amount of up to $8.0 million of Earnout Payments
View on SEC.gov